Notably, in aggressive breast cancers, HER2 is often co-expressed with junctional adhesion molecule-A (JAM-A), a cell–cell adhesion protein involved in tight junction formation in epithelial and endothelial cells, further supporting tumor progression and metastatic [197, 198].. Here, ERBB2 is linked to breast cancer.